Results 41 to 50 of about 19,166 (184)

Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components

, 2013
Spirochetes belonging to the Borrelia (B.) burgdorferi sensu lato complex differ in their resistance to complement-mediated killing, particularly in regard to human serum.
Christine Skerka, Skerka, Christine, Schwab, Jasmin, Peter Kraiczy (36173), Jasmin Schwab (105418), Christine Skerka (105424), Zipfel, Peter F., Richter, Dania, Peter Kraiczy, Peter F Zipfel, Dania Richter (105422), Franz-Rainer Matuschka, Peter F. Zipfel, Kraiczy, Peter, Reinhard Wallich (57833), Matuschka, Franz-Rainer, Dania Richter, Claudia Hammerschmidt, Wallich, Reinhard, Hammerschmidt, Claudia, Reinhard Wallich, Jasmin Schwab, Claudia Hammerschmidt (105420), Peter F. Zipfel (105431), Franz-Rainer Matuschka (105426)   +24 more
core   +1 more source

Complement-targeted therapies for transplant-associated thrombotic microangiopathy: recent advances

Frontiers in Pharmacology
Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication of hematopoietic stem cell transplantation in which systemic complement activation induces endothelial injury, leading to microangiopathic hemolytic anemia ...
Taichiro Tokura, Taichiro Tokura, Sayuri Motomura   +2 more
doaj   +1 more source

Successful treatment of a PNH patient non‐responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan) [PDF]

British Journal of Haematology, 2019
Contains fulltext : 218318.pdf (Publisher’s version ) (Open Access)
Saskia Schols, Miles A. Nunn, Ian Mackie, Wynne Weston‐Davies, Jun‐ichi Nishimura, Yuzuru Kanakura, Nicole Blijlevens, Petra Muus, Saskia Langemeijer   +8 more
openaire   +4 more sources

The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway

, 2021
Contains fulltext : 242823.pdf (Publisher’s version ) (Open Access)The complement system is an important part of innate immunity. Complement activation leads to formation of convertase enzymes, switch of their specificity from C3 to C5 ...
Heuvel, L.P.W.J. van den, Velden, T.J.A.M. van der, Kar, N.C.A.J. van de, Maas, R.J.F., Volokhina, E.B., Michels, M.A.H.M.   +5 more
core   +1 more source

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment [PDF]

Kidney International, 2020
Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we evaluate the efficacy and safety of ravulizumab in adults with atypical hemolytic uremic syndrome presenting with thrombotic microangiopathy. In this global, phase 3, single arm
Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, Haller, Hermann, Babu, Sunil, Broeders, Nilufer, Lietar, Nicole, Brown, Fiona, Campbell, Philip, Chowdhury, Paramit, Kasimatis, Theo, Cirami, Lino, Caroti, Leonardo, Antognoli, Guilia, Delmas, Yahsou, Dobronravov, Vladimir, Gaeckler, Anja, Garrouste, Cyril, Greenwood, Gregory, Griffin, Siân, Huang, Chiu-Ching, Chen, I-Ru, Huang, Susan, Kim, Jin Seok, La Manna, Gaetano, Comai, Giorgia, Cappuccilli, Maria, Le Quintrec, Moglie, Jeantet, Guillaume, Fumie, Iino, Luque, Yosu, Menne, Jan, Morelle, Johan, Goffin, Eric, Muhlfeld, Anja, Nagaraj, Shashi, Arepally, Gowthami, Oh, Doyeun, Okumi, Masayoshi, Terente, Manuel Praga, Gutierréz, Elena, Rodriguez, Paola, Provot, Francois, Schönermarck, Ulf, Fischereder, Michael, Terrada, Natalia Ramos, Seitz-Polski, Barbara, Favre, Guillaume, Boyer-Suavet, Sonia, Vinogradova, Maria, Kirsanova, Tatiana, Wong, Edwin K.S.   +60 more
openaire   +6 more sources

Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy

Blood Advances
: Paroxysmal nocturnal hemoglobinuria (PNH) and primary complement–mediated thrombotic microangiopathy, also known as atypical hemolytic uremic syndrome (aHUS), are hematologic disorders characterized by dysregulation of the complement system leading to ...
Thalia Padilla Kelley, Hannah King, Aditya Malhotra, Thomas G. DeLoughery, Kylee Martens, Joseph J. Shatzel   +5 more
doaj   +1 more source

Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi

, 2010
Background: One virulence property of Borrelia burgdorferi is its resistance to innate immunity, in particular to complement-mediated killing. Serum-resistant B.
Teresia Hallström, Hallström Teresia, Christine Skerka, Beckhaus Tobias, Skerka, Christine, Karas Michael, Hannes Eberhardt, Michael Karas, Barbara Uzonyi, Corinna Siegel, Kraiczy Peter, Eberhardt, Hannes, Uzonyi Barbara, Zipfel, Peter F., Beckhaus, Tobias, Peter Kraiczy, Karas, Michael (Prof. Dr.), Stevenson, Brian, Peter F Zipfel, Stevenson Brian, Uzonyi, Barbara, Brian Stevenson, Peter F. Zipfel, Siegel, Corinna, Hallström, Teresia, Kraiczy, Peter, Tobias Beckhaus, Eberhardt Hannes, Skerka Christine, Wallich, Reinhard, Zipfel Peter F., Reinhard Wallich, Siegel Corinna, Karas, Michael, Wallich Reinhard   +34 more
core   +1 more source

Complement in the Pathophysiology of the Antiphospholipid Syndrome

Frontiers in Immunology, 2019
The antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). Complement is a system of enzymes and regulatory proteins of the innate immune system that plays a key role ...
Shruti Chaturvedi, Robert A. Brodsky, Keith R. McCrae, Keith R. McCrae   +3 more
doaj   +1 more source

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods ...
Pratap Singh, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
doaj   +1 more source

A Specific Inhibitor of Complement (C5)-Derived Chemotactic Activity in Serum from Patients with Systemic Lupus Erythematosus [PDF]

Journal of Clinical Investigation, 1978
In the course of examining polymorphonuclear leukocyte (PMN) chemotaxis in patients with systemic lupus erythematosus (SLE), we have found a previously undescribed serum inhibitor of complement (C5)-derived chemotactic activity. Serum from a 25-yr-old Black female with untreated SLE, when activated with zymosan, failed completely to attract either her ...
H D, Perez, M, Lipton, I M, Goldstein
openaire   +2 more sources